Patrick Dolezal

LifeSci Capital

Recent Quotes

"DRRX plans to respond to a complete response letter for Posimir."

— Patrick Dolezal, LifeSci Capital (2/27/19)
more >

"DRRX will move its alcoholic hepatitis program to Dr. Craig McClain."

— Patrick Dolezal, LifeSci Capital (1/7/19)
more >

"For DRRX's trial of DUR-928 for PSC, data are anticipated in 2018."

— Patrick Dolezal, LifeSci Capital (7/30/18)
more >

"DRRX began dosing of a DUR-928 Phase 2a trial in alcoholic hepatitis."

— Patrick Dolezal, LifeSci Capital (4/25/18)
more >

"DRRX began dosing of a DUR-928 Phase 2a trial in alcoholic hepatitis."

— Patrick Dolezal, LifeSci Capital (4/25/18)
more >

"DRRX has initiated dosing in a Phase IIatrial for DUR-928 in the treatment of primary sclerosing cholangitis."

— Patrick Dolezal, LifeSci Capital (2/27/18)
more >

"DRRX announced the FDA has accepted the NDA for Invidior's RBP-2000."

— Patrick Dolezal, LifeSci Capital (12/13/17)
more >

"DRRX intends to initiate a Phase 2 study of oral DUR-928 in Q4/17."

— Patrick Dolezal, LifeSci Capital (10/20/17)
more >



Due to permission requirements, not all quotes are shown.